New drug offers hope for dialysis Patients' unbearable itching
NCT ID NCT03802617
First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tested an experimental drug called MR13A9 in 247 adults on hemodialysis who had severe itching (uremic pruritus). The goal was to see if the drug safely reduces itch intensity compared to a placebo. Participants rated their worst daily itch on a 0-10 scale, and the main analysis looked at the change after 8 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UREMIC PRURITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Multiple Locations, Japan
Conditions
Explore the condition pages connected to this study.